Sagar Patel presents the REVELUTION trial comparing leuprolide versus relugolix effects on coronary plaque progression in 94 men with non-metastatic prostate cancer receiving pelvic radiotherapy.
ASCO 2025 overall survival analysis of enzalutamide plus androgen-deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC), ARCHES study.
SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.
ESMO 2025, PSMA-positive metastatic hormone-sensitive prostate cancer, [177Lu]Lu-PSMA-617, VISION trial, PSMAfore trial, PSMAddition trial, 68Ga-PSMA-11 PET/CT.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
ESMO 2024, High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC), Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically, catumaxomab (CAT), EpCAM+ tumor cells.
Thulium Fiber Laser Versus Holmium MOSES™ Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Prospective Clinical Study - Beyond the Abstract ...
(UroToday.com) The 2025 ESMO annual meeting featured a Presidential Symposium session and a presentation by Dr. Thomas B. Powles discussing results from IMvigor011, a phase 3 trial of ctDNA-guided ...
(UroToday.com) The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Daniel Petrylak discussing radiographic progression-free survival (rPFS) in patients ...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Daniel Petrylak discussing initial results of a ...
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...
EAU 2025, non-muscle invasive bladder cancer (NMIBC), DaBlaCa-15 Trial, Xpert® Bladder Cancer, Urinary Biomarker Test Xpert® Bladder Cancer Monitor for Guiding Cystoscopy, High-grade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results